Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?

Drug makers are racing to develop what is believed to be next-generation renal anemia therapies, called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, with at least five compounds in development in Japan that could offer an alternative to erythropoietin-stimulating agents (ESAs)...read more